U.S. MarketsSeptember 18 at 01:57 PM

US FDA approve Eli-Lilly's (LLY) Iluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

StockNow breaking-news AI analysis

The US FDA approved Eli Lilly's Iluriyo in combination with Verzenio for adults with ER+, HER2-, and ESR1-mutated advanced or metastatic breast cancer.

1 stocks

LLYEli Lilly & Co.$1,154.58Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

Pakistani Interior Minister will travel to Iran within the next few hours, according to sources cited by Al Hadath; to focus on the repercussions of the Houthi escalation on regional security

Fed

Fed Vice Chair of Supervision Bowman does not comment on monetary policy; Fed supervisors should have known about SVB vulnerabilities as early as March 2022, more than a year before the bank's failure

Politics